GAAP Financial Statements
Galera Therapeutics, Inc. (GRTX)
3 quarters · 1 annual periods · CIK 0001563577
Quarterly (3)
| Period | Form | Revenue | Gross Profit | Op. Income | Net Income | EPS (Basic) | EPS (Dil.) | Assets | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Q3 FY2025 | 10-Q | — | — | -$1.4M | -$1.4M | $-0.01 | $-0.01 | $5.0M | $4.5M |
| Q2 FY2025 | 10-Q | — | — | -$1.1M | -$1.1M | $-4.94 | $-4.94 | $6.0M | $5.2M |
| Q1 FY2025 | 10-Q | — | — | -$2.0M | -$1.6M | $-0.01 | $-0.01 | $7.7M | $6.7M |
Annual (1)
| Period | Form | Revenue | Gross Profit | Op. Income | Net Income | EPS (Basic) | EPS (Dil.) | Assets | Cash |
|---|---|---|---|---|---|---|---|---|---|
| FY FY2024 | 10-K | — | — | $209.5M | -$19.0M | $-0.34 | $-342.89 | $10.1M | $8.3M |
Source: SEC EDGAR XBRL filings. Per-period figures are pulled from the original 10-Q / 10-K / 20-F submissions. Balance-sheet items (Assets, Cash, Equity) are point-in-time at period end.